FDA lifts par­tial hold on Salarius' Ew­ing sar­co­ma drug tri­al

Hous­ton biotech Salarius Phar­ma­ceu­ti­cals has re­ceived some pos­i­tive news from the FDA.

Salarius an­nounced Tues­day that the agency re­moved a par­tial clin­i­cal hold from its Phase I/II tri­al for its LSD1 in­hibitor se­clidem­stat to treat the bone can­cer Ew­ing sar­co­ma. Last year, Salarius de­cid­ed to pause new en­roll­ments when an in­di­vid­ual died af­ter tak­ing the treat­ment, and Salarius re­port­ed the de­tails to the FDA. While the cause of death re­mains un­clear, it did qual­i­fy as a sus­pect­ed un­ex­pect­ed se­ri­ous ad­verse re­ac­tion (SUSAR).

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER